Aclaris Therapeutics (ACRS) vs Neurogene (NGNE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Aclaris Therapeutics (ACRS) has outperformed Neurogene (NGNE) over the past year, gaining 99.5% versus a gain of 2.6%. Over five years, ACRS leads with a -77.5% price change compared with -81.6% for NGNE. Aclaris Therapeutics is the larger company by market cap ($557.9 million vs $530.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACRS | NGNE |
|---|---|---|
| Share price | $3.79 | $26.50 |
| Market cap | $557.88M | $530.30M |
| 1-day change | +11.47% | +2.44% |
| YTD return | +25.91% | +28.64% |
| 1-year return | +99.47% | +2.59% |
| 5-year return | -77.45% | -81.65% |
| EPS (TTM) | $-0.58 | $-5.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.60 | $43.66 |
| 52-week low | $1.74 | $15.93 |
| Distance from 52-week high | -42.58% | -39.30% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +168.60% | +193.89% |
| Average volume | 2.48M | 247.13K |
| Shares outstanding | 147.20M | 20.01M |
| Employees | 69 | 131 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ACRS has outperformed NGNE by 96.9 percentage points over the past year.
- The two companies sit in different sectors: Aclaris Therapeutics in Health Care and Neurogene in Healthcare.
About Aclaris Therapeutics
ACRS stock →Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions.
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
About Neurogene
NGNE stock →Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.
Healthcare · Biotechnology · 131 employees
ACRS vs NGNE FAQ
Which is bigger, Aclaris Therapeutics or Neurogene?
Aclaris Therapeutics (ACRS) is larger, with a market capitalization of $557.88M compared with $530.30M for Neurogene (NGNE).
Which stock has performed better over the past year, ACRS or NGNE?
ACRS returned +99.47% over the past 12 months, compared with +2.59% for NGNE (price return, excluding dividends). Past performance does not predict future results.
Are Aclaris Therapeutics and Neurogene in the same industry?
No. Aclaris Therapeutics is in the Health Care sector, while Neurogene is in Healthcare.